Raiffeisen Bank International AG Acquires Shares of 90,000 Evolent Health, Inc. (NYSE:EVH)

Raiffeisen Bank International AG acquired a new position in Evolent Health, Inc. (NYSE:EVH - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 90,000 shares of the technology company's stock, valued at approximately $988,000. Raiffeisen Bank International AG owned approximately 0.08% of Evolent Health at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EVH. Pilgrim Partners Asia Pte Ltd purchased a new stake in Evolent Health in the fourth quarter valued at about $26,000. R Squared Ltd acquired a new position in shares of Evolent Health during the fourth quarter valued at about $31,000. AlphaQuest LLC raised its position in shares of Evolent Health by 21,650.0% in the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock valued at $34,000 after purchasing an additional 3,031 shares during the last quarter. Parkside Financial Bank & Trust raised its position in shares of Evolent Health by 90.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock valued at $56,000 after purchasing an additional 2,358 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in Evolent Health in the 4th quarter worth approximately $61,000.

Analyst Ratings Changes

EVH has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. cut their price target on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating on the stock in a research note on Monday, March 10th. UBS Group boosted their price objective on shares of Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a report on Friday, May 9th. Needham & Company LLC restated a "buy" rating and issued a $15.00 target price on shares of Evolent Health in a research note on Tuesday, May 13th. JMP Securities reaffirmed a "market outperform" rating and set a $13.00 price target on shares of Evolent Health in a research report on Monday, April 28th. Finally, Truist Financial dropped their price target on Evolent Health from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $17.79.

Insider Transactions at Evolent Health

In related news, CEO Seth Blackley purchased 55,225 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were purchased at an average price of $9.01 per share, with a total value of $497,577.25. Following the purchase, the chief executive officer now owns 762,217 shares of the company's stock, valued at $6,867,575.17. The trade was a 7.81% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Diane Holder bought 2,735 shares of the business's stock in a transaction dated Thursday, March 6th. The shares were bought at an average cost of $9.33 per share, with a total value of $25,517.55. Following the purchase, the director now directly owns 70,584 shares of the company's stock, valued at approximately $658,548.72. This represents a 4.03% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 74,000 shares of company stock valued at $666,315 in the last 90 days. 1.40% of the stock is currently owned by company insiders.

Evolent Health Stock Performance

Shares of NYSE EVH traded down $0.55 during trading on Thursday, reaching $7.46. 1,031,378 shares of the company traded hands, compared to its average volume of 2,404,469. The stock has a market cap of $875.22 million, a P/E ratio of -9.12 and a beta of 1.04. The firm's fifty day simple moving average is $9.54 and its 200 day simple moving average is $10.82. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health, Inc. has a 12-month low of $7.41 and a 12-month high of $33.63.

Evolent Health (NYSE:EVH - Get Free Report) last posted its earnings results on Thursday, May 8th. The technology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.02). Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The company had revenue of $483.65 million for the quarter, compared to analyst estimates of $460.15 million. During the same period last year, the business earned $0.34 earnings per share. The firm's revenue was down 24.4% on a year-over-year basis. As a group, research analysts anticipate that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.